Skip to main content
Clinical Trials/ISRCTN17050221
ISRCTN17050221Active, not recruitingUnknown

euroMuscular Electrical Stimulation for the treatment of Diabetic Neuropathy: A multi-centre, double-blind, pilot, randomised, sham-controlled trial (NMES-DN)

Imperial College London0 sites100 target enrollmentStarted: June 30, 2023Last updated:
Conditions

Trial Snapshot

Phase
Unknown
Status
Active, not recruiting
Enrollment
100

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Sex
All

Inclusion Criteria

  • 1. Aged =18 (no upper limit)
  • 2. Diagnosis of type 1 or type 2 diabetes based on World Health Organisation (WHO) definition
  • 3. Diagnosis of diabetic neuropathy based on:
  • 3.1. Symptoms of diabetic neuropathy
  • 3.2. Validated screening questionnaire Michigan Neuropathy Screening Instrument score of =4
  • 3.3. Nerve conduction study of at least one lower limb must have a sural sensory nerve action potential (SNAP) amplitude of <6 µV or absent
  • 4. Access to the internet at home to use the Revitive App (study smartphones will be provided)
  • 5. Personal mobile phone to receive text messages

Exclusion Criteria

  • 1. Lacks the capacity to provide informed consent
  • 2. Pregnant
  • 3. Implanted electronic, cardiac or defibrillator device
  • 4. Other causes of peripheral neuropathy (e.g. excessive drinking, low levels of vitamin B12 or other vitamins, syphilis, HIV, underactive thyroid gland)
  • 5. Current foot ulceration
  • 6. Severe vascular disease requiring invasive intervention
  • 7. Being treated for, or having the symptoms of, an existing deep vein thrombosis (DVT)
  • 8. Used a neuromuscular electrical stimulation (NMES) device within 1 year of randomisation

Investigators

Similar Trials